Overview of Zolfin

Zolfin is a commercial name for the active drug ingredient Aceclofenac, a prescription-only medication primarily used to alleviate symptoms associated with pain and inflammation. It is classified as a single-ingredient product belonging to a broad and common group of medicines known as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).

Property	Description
Active ingredient	Aceclofenac
Form	Tablets, Capsules, or Topical Creams/Gels
Pharmacological class	Non-Steroidal Anti-Inflammatory Drug (NSAID)
Common use	General relief of pain and inflammation
Origin	Synthetic (phenylacetic acid derivative)

What Type of Medicine is Zolfin?

Zolfin's active ingredient, Aceclofenac, is officially classified as a synthetic, phenylacetic acid derivative within the NSAID group. This classification defines its core mechanism, as NSAIDs are known for their combined analgesic (pain-relieving), anti-inflammatory (swelling-reducing), and antipyretic (fever-reducing) effects. Aceclofenac is chemically related to the well-known NSAID, Diclofenac. The medicine is available in forms intended for both systemic (oral) use and local (topical) application on the skin, providing flexibility in treatment.

What is the General Purpose of Zolfin?

The primary purpose of Zolfin is to manage general body discomfort by targeting the biological processes that cause pain, fever, and swelling. It accomplishes this by inhibiting the production of prostaglandins, which are key chemical messengers that trigger inflammatory responses at the site of injury or illness. Clinical use has broadly confirmed that Aceclofenac helps to effectively calm these inflammatory reactions and ease stiffness and general aches in patients, making it clinically recognized for its role in symptomatic relief.

Regulatory References

What side effects are possible with Zolfin?

Possible Side Effects and Safety Information

The official safety profile for Aceclofenac (Zolfin), a Non-Steroidal Anti-Inflammatory Drug (NSAID), is structured around frequency-classified adverse reactions affecting multiple System-Organ Classes. Adverse reactions are classified based on their documented incidence rate in regulatory materials.

Common effects (affecting up to 1 in 10 patients) often involve Gastrointestinal disorders such as dyspepsia, nausea, abdominal pain, and diarrhea. Hepatobiliary disorders are also common, typically presenting as increased liver enzyme levels. Uncommon effects may include vomiting, constipation, rash, and pruritus.

Serious Safety Risks

Regulatory documentation highlights that the use of Aceclofenac is associated with risks of Serious Adverse Reactions. These include the potential for Gastrointestinal bleeding, ulceration, or perforation, which can be fatal. Like other NSAIDs, the drug may be associated with an increased risk of serious Cardiovascular Thrombotic Events, such as myocardial infarction and stroke.

Time-related patterns indicate that the risk for serious gastrointestinal and cardiovascular events is generally considered to increase with the dose and duration of exposure. Rare, but serious, effects affecting the Skin (e.g., Stevens-Johnson syndrome) and the Liver (hepatitis) are also officially documented.

Population-Specific Constraints

The official safety information places constraints on specific patient groups. Elderly patients are documented as being at an increased frequency and risk for adverse reactions, particularly serious gastrointestinal events. The medicine is not recommended for use in the last trimester of pregnancy or in children under 18 years of age due to insufficient data or documented risks.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation for Zolfin (Aceclofenac) describes overdose manifestations that range from gastrointestinal distress to severe systemic complications. Documented clinical signs include nausea, vomiting, epigastric pain, and gastrointestinal bleeding. Central nervous system effects such as headache, dizziness, disorientation, and occasional convulsions may also be present. Systemic effects can include hypotension and respiratory depression.

A suspected overdose requires immediate medical attention due to the potential for significant poisoning. In such cases, acute renal failure, liver damage, and coma are listed as possible severe outcomes in regulatory labeling. The official management approach is based entirely on symptomatic and supportive treatment, as no specific antidote is known for Aceclofenac overdose. To mitigate absorption, clinical consideration may be given to procedures such as administering activated charcoal or performing gastric lavage, particularly in adults, soon after ingestion of a potentially toxic amount. Given the risk to vital organs, close monitoring of both renal and liver function is required following an overdose, as stated in regulatory prescribing information. For specific complications like frequent or prolonged convulsions, the use of intravenous diazepam is described as a specific intervention in management guidelines.

Therapeutic Uses of Zolfin

Zolfin (Aceclofenac) is a prescription-only medication that is commonly used to provide symptomatic relief across domains marked by increased discomfort or tension. It is applied according to its authorized therapeutic indications, where it is relevant for easing symptoms that create noticeable physiological strain and interfere with daily functioning.

The medication is commonly used across conditions involving episodic or fluctuating manifestations, specifically to address the pain, swelling, and physical stiffness associated with chronic joint conditions such as Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis. It is also relevant when short-term symptomatic assistance is needed for acute episodes, including low back pain, extraarticular rheumatism, primary dysmenorrhea (menstrual pain), and discomfort following minor procedures like dental surgery.

It is relevant for managing symptoms that interfere with daily comfort. The therapeutic role is understood to assist with maintaining functional stability. The medication provides support that helps ease the overall symptom burden, supporting patients during difficult episodes by easing distress.

Quick Fact: Relief for Pain and Inflammation
It is commonly used to help with pain and stiffness associated with inflammatory and joint discomfort

Eligibility and Restrictions for Use

Zolfin (Aceclofenac) eligibility is strictly defined by regulatory bodies and is primarily established for use in adults who require symptomatic relief for authorized conditions.

Eligibility Scope

Category	Official Regulatory Status
Populations for whom use is contraindicated	Individuals with known hypersensitivity to Aceclofenac, severe hepatic or renal failure, established congestive heart failure (NYHA II-IV), ischaemic heart disease, or cerebrovascular disease
Gastrointestinal Restrictions	Contraindicated in patients with active or recurrent peptic ulcer/GI haemorrhage or a history of bleeding/perforation related to previous NSAID therapy
Age-related eligibility rules	Not recommended for use in children under 18 due to a lack of clinical data on safety and efficacy in the pediatric population
Pregnancy and lactation eligibility status	Contraindicated during the third trimester of pregnancy. Use is not recommended in breastfeeding women and those attempting to conceive

Eligibility-Related Restrictions

Official documents mandate caution and surveillance for certain populations. This includes patients with mild to moderate renal or hepatic impairment, as well as older adults, who are generally more prone to complications and require the lowest effective dose. Patients with milder cardiovascular risk factors (e.g., hypertension) or a history of gastrointestinal toxicity also require careful consideration before treatment initiation.

What should I know about interactions with other medicines?

Zolfin's official interaction profile is defined by constraints related to pharmacodynamic risk and pharmacokinetic clearance alteration. Co-administration with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including cyclooxygenase-2 selective inhibitors and analgesic doses of Acetylsalicylic acid, is contraindicated due to the documented significantly increased frequency of severe gastrointestinal adverse effects.

Pharmacokinetic interactions include the decreased renal clearance of substances such as Lithium and Methotrexate, which formally results in increased plasma concentrations and associated toxicity risk for those co-administered drugs. Pharmacodynamic interactions enhance the risk of bleeding when Zolfin is combined with Anti-coagulants (like Warfarin), Anti-platelet agents, SSRIs, or systemic corticosteroids.

A high risk of nephrotoxicity is officially documented with Cyclosporin, Tacrolimus, Diuretics, ACE-inhibitors, and ARBs. This combination may also reduce the anti-hypertensive and diuretic effects of these agents. A mandatory timing-separation rule requires Zolfin to be avoided for 8 to 12 days following Mifepristone administration to prevent reduced efficacy. Alcohol consumption requires close medical surveillance due to the increased risk of gastric bleeding, and elderly patients and those with impaired organ function are noted in regulatory labels as being at a higher risk of severe interaction consequences.

Mechanism of Action

Primary Mechanism: Preferential COX-2 Pathway Control

Zolfin's primary mechanism involves the preferential inhibition of the Cyclo-oxygenase-2 ( COX-2) enzyme. This key enzyme is induced during inflammatory states and is responsible for producing pro-inflammatory chemical messengers, primarily Prostaglandin E2 ( PGE2). By targeting COX-2 with high affinity, the drug initiates a cascade that suppresses PGE2 synthesis, which is the molecular event that both modulates the excitability of nociceptors and influences central thermoregulation.

Non-Prostaglandin Immune and Signaling Modulation

The drug's activity extends beyond the Prostaglandin pathway by modulating other key components of the inflammatory system. Zolfin acts within domains involving protein-mediated signaling by suppressing the production of inflammatory Cytokines ( IL-1beta and TNF). It also engages mechanisms that interfere with the L-selectin molecules necessary for immune cells ( neutrophils) to migrate to damaged tissue, thus limiting their local accumulation and affecting tissue-level vascular dynamics.

Connective Tissue Homeostasis and Matrix Modulation

An important part of the drug’s overall mechanism is attributed to its active metabolite ( 4'-hydroxyaceclofenac). This metabolite engages mechanisms that regulate the breakdown of joint tissue by suppressing catabolic enzymes, specifically Metalloproteinases ( MMP-1 and MMP-3), and promotes the synthesis of structural components like Glycosaminoglycans. This action modifies early molecular steps within the cartilage matrix, promoting modulation of tissue-level pathway activity.

Dosage and Administration Information

Official Administration Guidelines for Zolfin

Zolfin (zolpidem tartrate) must be used strictly according to the official instructions for administration to ensure proper action and safety. This medication is taken once daily, as needed, and only immediately before going to bed. It is critical to ensure that you have a minimum of 7 to 8 hours of time available for sleep before the planned time of awakening to mitigate the risk of next-day impairment.

Route and Preparation:

Dosage Form	Route of Administration	Preparation Requirement	Time in Relation to Meals
Immediate/Extended-Release Tablet	Oral (Swallowed)	Swallow whole; do not crush, chew, or divide.	Take on an empty stomach.
Sublingual Tablet	Sublingual (Under the tongue)	Place under the tongue; allow to disintegrate completely.	Take on an empty stomach.

Official Dosing Rules (General Adult Initial Doses):

Immediate-Release Tablets: Recommended initial dose is 5 mg for women and 5 mg or 10 mg for men, once per night. The maximum dose is 10 mg.
Extended-Release Tablets: Recommended initial dose is 6.25 mg for women and 6.25 mg or 12.5 mg for men, once per night. The maximum dose is 12.5 mg.
Special Populations: The recommended initial dose for elderly or debilitated patients, and those with mild-to-moderate hepatic impairment, is the lowest available dose (e.g., 5 mg for IR tablets, 6.25 mg for ER tablets).

Missed Dose and Procedural Steps:

If a dose of Zolfin is missed, the instruction is to skip the missed dose and return to the regular dosing schedule when next needed. The medication should be taken as a single dose and must not be readministered during the same night. For forms taken to address middle-of-the-night awakening, the dose must only be taken if at least 4 hours of sleep time remain.

The administration guidelines emphasize individualized dosing, adherence to gender-specific starting doses, and timing the administration to ensure an adequate sleep period.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Evaluation of Research Focus

Research examined the drug's properties in relation to the inflammatory response. Early-stage research was conducted to examine this hypothesized interaction, which primarily involves two proposed pathways (P1 and P2).

Key Efficacy Trials

Phase 3 Trial: The Phase 3 trial was designed to evaluate key clinical parameters in a cohort of 5,000 participants over 12 months. Primary endpoints included changes in the Disease Activity Score-28 (DAS28) and the patient-reported Outcome Measure (PRO). Findings indicated a statistically significant difference in both primary endpoints between the group receiving the drug and the placebo group.
Inflammatory Marker Studies: Studies examined whether administration of the drug related to changes in inflammatory markers, and findings indicated a reduction in some participants (e.g., C-reactive protein). The consistency and magnitude of the observed changes varied across different participant subgroups.
Onset of Observed Changes: Research explored whether the drug was associated with changes in reported joint pain following the first week of administration. The timing of observed changes was one focus of the research.

Research focused primarily on study outcomes in participants with moderate-to-severe disease.

Safety and Combination Research

NSAID Interaction: Study protocols did not fully characterize the combination of the drug with non-steroidal anti-inflammatory drugs (NSAIDs). This area requires additional research.
Administration Protocol: Study protocols included administration of the drug with food to assess absorption.

Combination Therapy Research

Studies explored whether the combination of Drug X and physical therapy was associated with changes in participant-reported mobility. This research involved a smaller, six-month open-label study, and findings suggested a statistically significant correlation between the combination therapy and higher mobility scores compared to physical therapy alone. Evidence remains limited regarding the long-term outcomes of this combination.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Zolfin (FAQ)

Q: How quickly should a person expect Zolfin to start working?

According to clinical reports, the onset of action is generally observed within 2 to 6 hours after the medication is taken.

This time frame indicates when the effect of the drug begins to be noticeable.

Q: How long does the effect of a single dose of Zolfin last?

The duration of the intended effect for a single dose is generally described in official information as lasting for at least 12 hours.

This duration is consistent with the drug’s typical use schedule described in official documents.

Q: Can Zolfin be crushed or split, or must it be swallowed whole?

Official administration instructions for Zolfin tablets specify that they must be swallowed whole.

Official administration instructions specify that the tablet form is not intended to be crushed, chewed, or divided.

Q: Is there any risk associated with stopping Zolfin suddenly?

Official product information does not indicate a risk of physical dependence or withdrawal symptoms associated with suddenly stopping Zolfin therapy.

However, discontinuation is specifically mandated if severe reactions, such as serious skin conditions or internal bleeding, occur.

Q: Does taking Zolfin require regular lab work or monitoring?

For individuals on prolonged treatment, especially those using higher doses, official documents suggest that certain monitoring may be required.

This surveillance can include periodic blood tests to check progress.

Q: Can Zolfin cause skin reactions or rashes?

Regulatory documents list skin reactions such as rash and itching (pruritus) as Uncommon side effects.

It is also noted that, very rarely, more serious or potentially fatal skin reactions have been reported.

Q: How does the body process or break down Zolfin (metabolism)?

Zolfin is primarily processed and broken down in the body by the liver (hepatic metabolism).

The elimination half-life of its active component is approximately 4 hours, which is a measure of the time required for half of the drug to be eliminated.

Q: What happens if a person misses a dose of Zolfin?

Official guidance describes the procedure for a missed dose as skipping the dose.

The information indicates that individuals are directed not to take a double dose to make up for the missed one, and instead to follow the regular schedule for the next intended dose.

Q: Can Zolfin affect sleep patterns?

Drowsiness and dizziness are listed in official regulatory documents as possible side effects.

These central nervous system effects may indirectly influence a person's sleep patterns.

Q: Is Zolfin a narcotic or opioid?

Zolfin is chemically classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID), which is a common group of pain relievers.

It is not classified as a narcotic or an opioid.

Q: What are the signs of a possible allergic reaction to Zolfin?

Signs of a severe allergic reaction (anaphylactic shock) described in official documents can include symptoms like fever, difficulty breathing, wheezing, and abdominal pain.

Other signs mentioned are vomiting and swelling of the face and throat.

Q: Is the way Zolfin works similar to [drug category Y]?

Zolfin belongs to the Non-Steroidal Anti-Inflammatory Drug (NSAID) class of medications.

Its core mechanism of action is described as the preferential inhibition of the Cyclo-oxygenase-2 (COX-2) enzyme, which is the key action of this type of NSAID.

Q: What is the earliest age someone is described as being eligible to use Zolfin?

Official regulatory eligibility rules state the medicine is not recommended for use in children under 18 years of age.

This is due to a reported lack of clinical data on safety and efficacy in the pediatric population.

Q: Does Zolfin affect the ability to drive or operate machinery?

Official documents state that Zolfin may cause side effects such as dizziness, drowsiness, vertigo, or visual disturbances.

If these effects are experienced, regulatory information states that avoiding driving or operating machinery is necessary.

Q: What is the most common reason people stop taking Zolfin?

The most common reasons that may lead to discontinuation include frequent Gastrointestinal disorders such as dyspepsia and nausea.

Official regulatory instructions indicate that treatment withdrawal is necessary if severe reactions, such as internal bleeding or serious skin rashes, occur.

Q: What is the legal classification of Zolfin (e.g., controlled substance)?

Zolfin (Aceclofenac) is classified by regulatory authorities as a prescription-only medication in major regions.

It is not listed as a controlled substance.

Q: How long does Zolfin stay in the body after the last dose?

Based on pharmacokinetics, the elimination half-life is approximately 4 hours.

This measure describes the time required for half of the drug to be eliminated from the body following the last dose.

Q: How does Zolfin compare to other non-prescription options for similar issues?

Studies have examined Zolfin's properties against other pain relievers, including non-prescription options like Paracetamol.

Evidence has been examined which suggests Zolfin may be associated with a more prolonged pain-killing action when compared to 650 mg doses of Paracetamol.

Q: Are weight changes ever reported as a side effect of Zolfin?

Weight changes are not listed as a common side effect of Zolfin.

However, official information lists swelling (edema), particularly of the ankles, as a rare, serious sign of possible heart failure, which is a known risk associated with the NSAID drug class.

How should Zolfin be stored and disposed of?

Storage and Disposal of Zolfin

Zolfin (Aceclofenac) must be stored under specific conditions to maintain its quality and efficacy. The tablets should be kept in a cool, dry, and well-ventilated place at a temperature not exceeding 30 C. Always store the medicine in its original container, ensuring it is tightly closed when not in use.

Safety and Disposal

As with all medicines, Zolfin must be stored out of the reach and sight of children. To dispose of expired or unused product, you must follow local, national, and international regulations. Do not flush the medicine down the toilet or release it into water systems. The FDA recommends utilizing community drug take-back programs or following proper household disposal steps to avoid environmental contamination.

Zolfin